We are live on ! Find out more
EI

EAM Investors Portfolio holdings

AUM $866M
1-Year Est. Return 377.14%
This Fund
S&P 500
This Quarter Est. Return
+35.79%
1 Year Est. Return
+377.14%
3 Year Est. Return
+5,228.32%
5 Year Est. Return
+49,813.07%
10 Year Est. Return
+19,957,621.5%
AUM
$898M
AUM Growth
+$25.6M
Cap. Flow
-$107M
Cap. Flow %
-11.88%
Top 10 Hldgs %
9.87%
Holding
377
New
123
Increased
22
Reduced
103
Closed
109

Sector Composition

Rank Sector Weight
1 Healthcare 29.73%
2 Technology 20.64%
3 Industrials 18.62%
4 Financials 7.66%
5 Consumer Discretionary 6.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SENEA icon
226
Seneca Foods Class A
SENEA
$1.21B
$810K 0.09%
7,325
+462
+7% +$52.8K
MRAM icon
227
Everspin Technologies
MRAM
$405M
$803K 0.09%
+86,512
New +$823K
EGAN icon
228
eGain
EGAN
$201M
$802K 0.09%
77,970
KRMD icon
229
KORU Medical Systems
KRMD
$164M
$794K 0.09%
+136,716
New +$655K
AP icon
230
Ampco-Pittsburgh
AP
$193M
$791K 0.09%
+148,395
New +$410K
RLMD icon
231
Relmada Therapeutics
RLMD
$519M
$785K 0.09%
+162,552
New +$545K
ESQ icon
232
Esquire Financial Holdings
ESQ
$1.14B
$784K 0.09%
7,683
-3,724
-33% -$377K
TCBX icon
233
Third Coast Bancshares
TCBX
$738M
$766K 0.09%
20,158
-5,628
-22% -$215K
FOSL icon
234
Fossil Group
FOSL
$318M
$755K 0.08%
200,894
MNPR icon
235
Monopar Therapeutics
MNPR
$799M
$743K 0.08%
11,373
-3,256
-22% -$266K
DSGN icon
236
Design Therapeutics
DSGN
$876M
$741K 0.08%
+78,949
New +$618K
LCTX icon
237
Lineage Cell Therapeutics
LCTX
$274M
$739K 0.08%
442,221
DMAC icon
238
DiaMedica Therapeutics
DMAC
$364M
$728K 0.08%
+91,425
New +$684K
IZEA icon
239
IZEA Worldwide
IZEA
$61.3M
$728K 0.08%
166,138
CXDO icon
240
Crexendo
CXDO
$222M
$717K 0.08%
+110,852
New +$725K
FULC icon
241
Fulcrum Therapeutics
FULC
$297M
$697K 0.08%
+61,620
New +$627K
DERM icon
242
Journey Medical
DERM
$177M
$689K 0.08%
89,389
CODA icon
243
Coda Octopus Group
CODA
$120M
$686K 0.08%
+73,722
New +$666K
STLN
244
Starling Oncology, Inc. Common Stock
STLN
$641M
$650K 0.07%
182,509
ENTA icon
245
Enanta Pharmaceuticals
ENTA
$400M
$646K 0.07%
+40,952
New +$520K
AMLX icon
246
Amylyx Pharmaceuticals
AMLX
$2.54B
$643K 0.07%
53,256
-21,855
-29% -$297K
IMMX icon
247
Immix Biopharma
IMMX
$692M
$632K 0.07%
+120,856
New +$497K
XERS icon
248
Xeris Biopharma Holdings
XERS
$1.37B
$629K 0.07%
80,154
-522,947
-87% -$4.12M
PPIH
249
Perma-Pipe International
PPIH
$215M
$620K 0.07%
20,421
KWY
250
Kingsway Corp
KWY
$293M
$580K 0.06%
43,088
-20,730
-32% -$284K

Similar funds

EAM Investors's Q4 2025 Portfolio in Review

As of Q4 2025, EAM Investors held 377 positions worth $898M, up 2.9% from $872M the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.

EAM Investors withdrew a net $107M in Q4 2025, closing 109 positions and reducing 103 holdings. Its most notable exit was AeroVironment, an estimated $8.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 17% a quarter earlier, followed by Technology and Industrials.

Against the trend, EAM Investors opened a new position in Nextpower Inc worth $6.78M.

  • EAM Investors's largest Q4 2025 buy was Nextpower Inc: 77,814 shares worth $6.78M.
  • EAM Investors added most to Solaris Energy Infrastructure in Q4 2025, an estimated $4.92M increase.
  • EAM Investors's biggest Q4 2025 reduction was Kratos Defense & Security Solutions, cutting an estimated $7.93M.
  • EAM Investors fully exited AeroVironment in Q4 2025, selling an estimated $8.08M.
  • EAM Investors's ten largest holdings make up 9.9% of its $898M portfolio in Q4 2025.
  • EAM Investors opened 123 new positions and closed 109 in Q4 2025.
  • EAM Investors's portfolio value rose 2.9% quarter-over-quarter to $898M.

Based on EAM Investors's 13F filing for Q4 2025, filed 12 Feb 2026.